Tesamorelin Dosage Chart: The Sequence That Produced It
Where the numbers came from, in the order they were produced, and the point at which the sequence stops covering you.
A dosage chart is the last step in a sequence, and its authority is entirely inherited from the steps before it. For most compounds covered here those steps are missing. Tesamorelin is the rare case where they exist, so it is worth walking the sequence in order.
Step 1: a trial programme
Around 24 studies are registered on ClinicalTrials.gov under the name. That is a real programme by the standards of this category, where the usual answer is zero or a single record of doubtful provenance.
Step 2: a regulator reviewed it
The FDA approved the compound. It is marketed as EGRIFTA, latterly EGRIFTA SV, under biologics licence application BLA 022505, held by Theratechnologies, supplied as a prescription powder for reconstitution.
This is the step that does not exist for BPC-157, MOTS-c or epithalon. Someone outside the sponsor read the data and was accountable for the conclusion.
Step 3: the label fixed an indication, and it is narrow
Here is where the sequence turns out to cover less than people assume. The approved indication is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
The same section carries a limitation of use: long-term cardiovascular safety has not been established, and prescribers are directed to weigh risk and benefit in patients who have not seen a reduction in visceral adipose tissue.
One population. One outcome. A stated gap in the long-term safety record.
Step 4: the chart
A tesamorelin dosage chart restating those quantities is reporting something a regulator authorised, which is a stronger provenance than anything available for the unapproved compounds on this site.
What the chart cannot carry across is the indication. The quantities were studied in one population for one endpoint, and the authorisation is attached to that pairing. Presenting the same figures for general body composition is a step outside the sequence, and the numbers look identical on either side of that line.
Where the sequence stops
It stops at the edge of the indication. Inside it, there is a trial programme, a regulatory review, a label and a chart, in that order. Outside it, there is a compound with good characterisation being used for something the approved evidence did not examine.
Both things are true at once, and a chart that states only the first is telling you half of what you need.